Physician profile
Ryan Michael Schell
NPI 1629428578
$7,486.34
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,204 · 2020: $537 · 2021: $2,045 · 2022: $366 · 2023: $3,139 · 2024: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,881 · Food and Beverage: $1,239 · Education: $215.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,880.86 |
| Food and Beverage | $1,238.73 |
| Education | $214.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Elite Orthopedics, LLC | $3,380.28 | 2019-2024 | |
| Zimmer Biomet Holdings, INC. | $1,369.28 | 2019-2024 | Comprehensive Shoulder System, Persona, Dvr Anatomic Kickstand |
| Arthrex, INC. | $1,069.96 | 2023 | |
| Stryker Corporation | $345.51 | 2020 | |
| Medical Device Business Services, INC. | $319.98 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $201.49 | 2022-2023 | Dupixent |
| Depuy Synthes Sales INC. | $172.77 | 2020-2024 | Lcp |
| Radius Health, INC. | $77.57 | 2022-2023 | Tymlos |
| Grifols USA, LLC | $73.83 | 2022-2023 | Prolastin-C Liquid |
| Amgen INC. | $51.34 | 2022-2023 | Evenity, Prolia |
| Heraeus Medical, LLC. | $47.96 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.25 | 2022-2023 | Jardiance |
| Carbofix Orthopedics INC | $38.85 | 2023 | |
| Astrazeneca Pharmaceuticals Lp | $31.40 | 2023 | Fasenra, Tezspire |
| Janssen Biotech, INC. | $28.56 | 2023 | Stelara, Simponi, Remicade |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ermi LLC | $23.95 | 2023 | |
| Medtronic, INC. | $23.52 | 2023 | Intellis Adaptivestim |
| Sanara Medtech INC. | $20.64 | 2024 | Celleraterx |
| Ucb, INC. | $20.31 | 2022 | |
| Novo Nordisk INC | $19.60 | 2022 | |
| Merck Sharp & Dohme LLC | $19.49 | 2023 | Verquvo, Belsomra, Steglatro |
| Mylan Specialty L.P. | $17.82 | 2022 | |
| Bioventus LLC | $16.35 | 2023 | Durolane |
| Qol Medical, LLC | $15.33 | 2022 | |
| Axsome Therapeutics, INC. | $14.78 | 2023 | Sunosi |
| Daiichi Sankyo INC. | $14.40 | 2023 | Injectafer |
| Pacira Therapeutics, INC. | $13.12 | 2019 | |
| Convatec INC. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Schell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.